Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
Open Access
Abstract
Immunotherapy with immune checkpoint inhibitors represents nowadays a marked improvement in cancer treatment. Nevertheless, they can cause severe toxicities that put the patient at high risk, often requiring aggressive treatment. We present the case of a female patient who developed a severe immune-related adverse reaction to Pembrolizumab prescribed for melanoma treatment. Her array of symptoms, which presented a few days after last drug administration, consisted of severe neurological deficit, severe renal failure, polymyositis, and hyperthyroidism. Treatment required the immediate interruption of the trigger drug, infusion of high dose steroids, renal replacement therapy, plasmapheresis, and methimazole, as will be further discussed.Keywords
This publication has 16 references indexed in Scilit:
- Renal effects of immune checkpoint inhibitorsNephrology Dialysis Transplantation, 2016
- Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the LiteratureArthritis Care & Research, 2016
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Pembrolizumab (Keytruda)Human Vaccines & Immunotherapeutics, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant MelanomaJournal of Clinical Oncology, 2012
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008